



Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024

January 31, 2024

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 31, 2024-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a live webcast on Wednesday, February 14, 2024 at 8:00 a.m. ET to review fourth quarter and full year 2023 financial results and discuss recent business updates.

The webcast can be accessed on the Investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.

About Sage Therapeutics

Sage Therapeutics (Nasdaq: SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. Sage was founded in 2010 and is headquartered in Cambridge, Mass. Find out more at www.sagerx.com or engage with us on [Facebook](#), [LinkedIn](#), [Instagram](#), and [X](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240131967265/en/): <https://www.businesswire.com/news/home/20240131967265/en/>

Investor Contact

Ashley Kaplowitz
786-252-1419
ashley.kaplowitz@sagerx.com

Media Contact

Matthew Henson
917-930-7147
matthew.henson@sagerx.com

Source: Sage Therapeutics, Inc.